Topotecan for Injection is indicated for small cell lung cancer sensitive disease after failure of first-line chemotherapy, and is also indicated for use in combination therapy with Cisplatin for stage IV-B, recurrent, or persistent carcinoma of the cervix not amenable to curative treatment with surgery and/or radiation therapy.
Kadmon Pharmaceuticals chief commercial officer Adriann Sax said Topotecan for Injection is the second in a series of generic oncology products which Kadmon expects to market through its wholesale specialty pharmaceuticals sales network.
"These generic products are part of an expanding commercial platform supporting Kadmon’s pipeline of pioneering, targeted medicines in oncology and other disease areas," Sax said.
Recently, Kadmon Pharmaceuticals has acquired Three Rivers Pharmaceuticals, a privately held specialty pharmaceuticals company based in Warrendale, Pennsylvania.
Kadmon Pharmaceuticals explores new understandings in molecular biology to develop therapies that target the metabolomic or signaling pathways associated with disease, including novel anti hepatitis C therapies.